Lukas is dedicated the research of Memory T cell (LuLym-T®) to improve clinical outcome of cancer treatment.
All Immunotherapy technologies developed by Lukas adhere to the highest principles:
- T cell: Our QC team ensure that all memory T cells are cultured to an amount of 10^9~10^10 with purity of more than 95%.
- Timing: Lukas has been cooperating with hospitals to develop different protocols for different cancers to ensure that all cells are administered at the most suitable time during conventional treatments.
- Testament: Evidence-based medicine has been published in the international medical journals.
- GTP:All our cells are cultured in GTP labs with world-class standards to ensure the highest safety standards.
Lukas`s T cell technology has been published in the international medical journals: Lancet and Gastroenterology. The results of two studies showed that immunotherapy could significantly lower duration of cancer recurrence and increase survival rate.
Cooperation projects and needs
1. Partnership for cell therapy projects of regulation governing specific cellular therapeutic technology
2. Partnership for B to B and B to C of medical services domestic and international markets, especially in China and southbound countries.
3. Further research and development collaboration